R&D spend driving China pharma co’s

Companies are narrowing the gap

China is not a powerhouse of innovation, yet, but it is certainly trying to pay its way into that particular status. This willingness to spend in R&D – to pay to talent, buy innovative companies and seek out new technologies – is particularly visible in the pharmaceutical and biotechnology space. And it is working.

read more

Australia’s largest life science fund

Australia’s life science sector outperforms in research… falls short on commercialisation.

It is no surprise that the life science sector including pharmaceutical, medical devices etc. is one of the hottest investment destinations. Last month, Australian investment company Brandon Capital closed the largest life science fund to date in Australia after raising A$200 million (US$155 million). The fund is set to fill the funding gap of the country’s medical technology commercialisation.

read more

China Issues Biosimilar Guidelines Draft

A long-awaited set of guidelines for a billion-dollar market.

After years of waiting, Chinese biosimilar makers will soon have a set of guidelines to follow.

This post on Thomson Reuters Life Sciences Connect news blog (HERE) outlines the  industry’s reaction to the draft biosimilar guidelines.

The global biologics market is experiencing a golden age over the current decade. As drug development progresses, it’s time for biopharmaceutical companies to start reaping its rewards. The market is expected to grow more than 80 percent from $138 billion in 2010 to $253 billion by 2020, according to Sandoz international GmbH. And $2 billion of this will be coming from biosimilar products.

read more